Skip to content

A Randomized Controlled Study on the Efficacy of Liver Resection and TACE Combined with Radiotherapy in Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombus

A Multicenter Prospective Randomized Controlled Study the Efficacy of Liver Resection and TACE Combined with Radiotherapy in Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036002
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma, combined portal vein tumor thrombosis

Interventions

Liver resection (LR):Liver resection

Sponsors

Third Affiliated Hospital of the Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Between 18-70 years; 2) Clinical diagnosis of hepatocellular carcinoma (clinical diagnostic criteria for hepatocellular carcinoma: meet the diagnostic criteria for primary liver cancer diagnosis and treatment in 2019); 3) Imaging (MR or CT) showed clear tumor thrombus, which did not reach the main portal vein and the contralateral side, (Cheng's classification I, II); 5) Have not received other anti-tumor treatments in the past; 6) Tumors and tumor thrombi are located on the same side of the liver and are resectable (the residual liver volume in patients without cirrhosis accounted for >30% of the standard liver volume, and in patients with cirrhosis, the residual liver volume accounted for > 40% of the standard liver volume; after evaluation Liver function can be compensated after surgery.) 7) ECOG 0-2; 8) Child-Pugh A; 9) Know the research process and agree to participate, sign relevant informed consent and other documents

Exclusion criteria

Exclusion criteria: 1) Have a history of other tumors; 2) The tumor thrombus exceeds the main portal vein or reaches the contralateral portal vein; 3) Combined with multiple metastases in the liver or distant metastases; 4) With portal hypertension (PLT<50*109/L, gastroscope suggests severe esophageal and gastric varices or a history of upper gastrointestinal bleeding, cavernous transformation of portal vein).

Design outcomes

Primary

MeasureTime frame
Overall Survival;Median Survival Time;

Secondary

MeasureTime frame
Quality of Life Score;Adverse Events;

Countries

China

Contacts

Public ContactZhou Weiping

Third Affiliated Hospital of the Second Military Medical University

ehphwp@126.com+86 13601616763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026